©
Enara Bio
The company's new investors, Pfizer Ventures and M Ventures, co-led the financing. Also joining as a new investor is the Francis Crick Institute, which participated in the round with all existing investors, including RA Capital, Samsara BioCapital, and SV Health Investors.
Kevin Pojasek, Ph.D., President & Chief Executive Officer of Enara Bio expressed enthusiasm and gratitude for the support:
We are delighted to have the backing of these sophisticated investors as we strive to develop novel immunotherapies that can provide durable clinical benefit for broad populations of cancer patients.
As well as a successful funding round, Enara Bio welcomed Rana Al-Hallaq, Partner at Pfizer Ventures, and Bauke Anninga, Investment Director at M Ventures, as new appointments to its Board of Directors.